deltatrials
Terminated PHASE4 NCT00764582

Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery

A Randomized, Observer-masked, Parallel-group, Multicenter Trial Evaluating the Ocular Penetration of 1.5% Levofloxacin Ophthalmic Solution and 0.5% Moxifloxacin Ophthalmic Solution in Subjects Undergoing Corneal Transplant Surgery

Sponsor: Santen Inc.

Conditions Corneal Transplantation
Interventions 0.5% moxifloxacin ophthalmic solution 1.5% levofloxacin ophthalmic solution
Updated 5 times since 2017 Last updated: Aug 24, 2009 Started: Sep 30, 2008 Primary completion: Mar 31, 2009

Listed as NCT00764582, this PHASE4 trial focuses on Corneal Transplantation and remains terminated or withdrawn. Sponsored by Santen Inc., it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE4

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE4

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE4

  5. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE4

    First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Santen Inc.
  • Vistakon Pharmaceuticals
Data source: Santen Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boynton Beach, United States
  • • Cincinnati, United States
  • • Great Rapids, United States
  • • Indianapolis, United States
  • • Kansas City, United States
  • • Portland, United States
  • • Springfield, United States
  • • Stony Brook, United States